ZURICH (Reuters) – An experimental drug from Novartis markedly shrank tumors in patients with advanced basal cell carcinoma, the most common form of skin cancer, according to the results of a mid-stage study published on Sunday. Basal cell carcinoma can be highly disfiguring and…
Source:Novartis skin cancer drug shrinks tumors in Phase II trial
Sunday, June 1, 2014
Novartis skin cancer drug shrinks tumors in Phase II trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment